Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
68results about "Neuropeptide Y" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Anti-obesity agents
InactiveUS20050176643A1Polypeptide with localisation/targeting motifPeptide/protein ingredientsBlood componentPYY Peptide
The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.
Owner:CONJUCHEM
Stable analogs of peptide and polypeptide therapeutics
InactiveUS7259234B2Prolong half-life in vivoLong durationNervous disorderPeptide/protein ingredientsProteolysisChemistry
The present invention relates to compositions of peptide and polypeptide analogs that are resistant to proteolysis, pharmaceutical uses thereof, and methods of preparation thereof.
Owner:BACH BIOSCI LLC
Peptides for the activation of the immune system in humans and animals
The present invention is directed to compositions and methods for the treatment of diseases comprising the administration of compositions comprising one or more peptide(s) having a stimulatory effect on the afflicted host's immune system. Specifically, the invention relates to methods comprising the use of cationic amphipathic peptides having an alpha-helical structure and effecting activation of macrophages when administered in a therapeutically sufficient amount. The methods of the present invention are useful for the treatment of, for example, infectious diseases or cancer.
Owner:MOR AMRAM
Compositions and methods for brain delivery of analgesic peptides
ActiveUS20130034572A1Lack of effectHigh selectivityNervous disorderAntipyreticNon invasivePharmacology
The present invention relates to non-invasive brain delivery technology for centrally-acting analgesic peptides. Specifically, the invention is directed to compounds comprising an antibody or fragment thereof capable of transmigrating across the blood brain barrier (BBB) and an analgesic peptide. Compositions and methods of using the compounds or compositions are also provided.
Owner:NAT RES COUNCIL OF CANADA
Compounds for control of appetite
This invention relates generally to neuropeptide Y (“NPY”) Y4 receptor agonists including pancreatic polypeptide (PP), analogs thereof, and peptide fragments of PP, e.g. PP(32-36), and analogs thereof, to pharmaceutical compositions containing such Y4 receptor agonists, and to methods for treatment of mammals using the same. The NPY Y4 receptor agonists may be administered to mammals either alone or in combination with NPY Y2 receptor agonists including peptide YY (PYY) (3-36), analogs thereof, and to peptide fragments of PYY(3-36), e.g. PYY(22-36) and PYY(25-36), and analogs thereof, such as to control food intake in mammals, blood pressure, cardiovascular response, libido, circadian rhythm, hyperlipidimia, chronic pancreatitis, and nonalcoholic fatty liver disease including nonalcoholic steatohepatitis.
Owner:CINCINNATI UNIV OF
Novel Anti-Obesity Agents
InactiveUS20080194486A1Polypeptide with localisation/targeting motifPeptide/protein ingredientsBlood componentPYY Peptide
The present invention relates to a compound comprising a PYY peptide or a functional derivative thereof, which is coupled to a reactive group. Such a reactive group is capable of reacting on a blood component so as to form a stable covalent bond therewith. The present invention also relates to a conjugate comprising such a compound which is covalently bonded to a blood component. Moreover, the invention also relates to a method of enhancing, in a patient, the anti-obesity activity of a PYY peptide or functional derivative thereof.
Owner:CONJUCHEM
Therapeutic peptides
Owner:GLAXOSMITHKLINE INTPROP DEV LTD
Process for the production of preformed conjugates of albumin and a therapeutic agent
The present invention provides processes for the production of preformed albumin conjugates. In particular, the invention provides processes for the in-vitro conjugation of a therapeutic compound to recombinant albumin, wherein a therapeutic compound comprising a reactive group is contacted to recombinant albumin in solution to form a conjugate. The processes provide for conjugation to albumin species of increasing homogeneity . The resulting conjugate is purified by chromatography, in particular hydrophobic interaction chromatography comprising phenyl sepharose and butyl sepharose chromatography.
Owner:CHANGSHAN KAIJIEJIAN BIOPHARMACEUTICAL DEV (HEBEI) CO LTD
Methods and Compositions Related to Improving Properties of Pharmacological Agents Targeting Nervous System
InactiveUS20090281031A1Improve blood-brain barrier permeabilityIncreased lipophilic characterNervous disorderPeptide/protein ingredientsNervous systemMedicine
Disclosed are compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system.
Owner:UNIV OF UTAH RES FOUND
Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an Anti-cancer immune response
InactiveUS20190240293A1Relieve symptomsLimited ability to cross blood brain barrierNervous disorderPeptide/protein ingredientsCancer researchNeuroregulator
Described herein are methods for treating a subject having or at risk of developing cancer administering a neuromodulating agent.
Owner:FLAGSHIP PIONEERING INNOVATIONS V INC
Peptide yy analogs
InactiveUS20060211610A1Promote weight gainEasy maintenanceBiocidePeptide/protein ingredientsPYY PeptidePYY receptors
The invention provides analogs of PYY. The invention also provides compositions and methods useful for controlling biological activities such as cell proliferation, nutrient transport, lipolysis, and intestinal water and electrolyte secretion.
Owner:IPSEN PHARMA SAS
Methods and compositions for the treatment of neurological disease
InactiveUS20050136036A1Treatment effectRelieve symptomsBiocideNervous disorderNucleic acid sequencingBiology
The present invention relates to a method for delivering a nucleic acid sequence encoding neuropeptide Y, or a derivative or functional fragment thereof, to a mammalian nervous system target cell. The expression of exogenous NPY, or a derivative or a functional fragment thereof in the target cell(s) provides therapeutic benefit for subjects afflicted with a neurological disorder.
Owner:NEUROLOGIX RESEARCH INC
Stable Analogs of Peptide and Polypeptide Therapeutics
InactiveUS20080051557A1Prolong half-life in vivoLong durationNervous disorderPeptide/protein ingredientsProteolysisChemistry
Owner:BACH BIOSCI LLC
Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
Owner:F HOFFMANN LA ROCHE & CO AG
Compounds and methods for 18F labeled agents
ActiveUS8557776B2Good water solubilityImprove bioavailabilityBiocidePeptide/protein ingredientsMedicineChemical compound
Owner:BAYER SCHERING PHARMA AG
Neuropeptide-2 receptor (y-2r) agonists
InactiveUS20100069307A1Impaired glucose tolerancePeptide/protein ingredientsMetabolism disorderDense Core VesiclesAgonist
Provided herein are neuropeptide-2 receptor agonists of the formula (I):Y—R1—R2—X—R3—R4—R5—R6—R7—R8—R9—R10—R11—R12—R13—R14—NH2 (I),as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
Owner:F HOFFMANN LA ROCHE INC
Methods and compositions related to improving properties of pharmacological agents targeting nervous system
InactiveCN101448513APolypeptide with localisation/targeting motifPeptide/protein ingredientsNervous systemMedicine
The present invention discloses compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system.
Owner:UNIV OF UTAH RES FOUND
Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
Provided herein are neuropeptide-2 receptor agonists of the formula (I):Y—R1—R2—X—R3—R4—R5—R6—R7—R8—R9—R10—R11—R12—R13—R14—NH2, (I)as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.
Owner:F HOFFMANN LA ROCHE & CO AG
Neuropeptides and their use for pest control
InactiveUS6884878B2Facilitates passage through the cuticleReduce in quantityBiocideAnimal cellsPest controlDense Core Vesicles
The present invention discloses novel pest control compounds comprising NPF polypeptides and methods for using such compounds in the control of pests.
Owner:UNIV OF FLORIDA RES FOUNDATION INC
Regulation of Specific Spinal Neurons Regulating Pain Transmission
ActiveUS20140255376A1Long-lasting and/or stable and/or reversiblePolypeptide with localisation/targeting motifTachykininsPeptide ligandNeuron
A chimeric toxin is disclosed comprising a peptide ligand specifically targeting neurons involved in pain processing; and a clostridial neurotoxin light chain, wherein the ligand is linked to the light chain. The methods of preparing such chimeric toxin and the method of using the chimeric toxin to regulate pain transmission are also disclosed.
Owner:RGT UNIV OF CALIFORNIA +1
Methods and compositions for the treatment of neurological disease
InactiveUS7723288B2Alters neuronal excitabilityRelieve symptomsBiocideNervous disorderDiseaseNucleic acid sequencing
The present invention relates to a method for delivering a nucleic acid sequence encoding neuropeptide Y, or a derivative or functional fragment thereof, to a mammalian nervous system target cell. The expression of exogenous NPY, or a derivative or a functional fragment thereof in the target cell(s) provides therapeutic benefit for subjects afflicted with a neurological disorder.
Owner:NEUROLOGIX RESEARCH INC
Compounds for control of appetite
ActiveUS20090227519A1Peptide/protein ingredientsMetabolism disorderPancreatic polypeptidomaPancreatic stent
This invention relates generally to neuropeptide Y (“NPY”) Y4 receptor agonists including pancreatic polypeptide (PP), analogs thereof, and peptide fragments of PP, e.g. PP(32-36), and analogs thereof to pharmaceutical compositions containing such Y4 receptor agonists, and to methods for treatment of mammals using the same. The NPY Y4 receptor agonists may be administered to mammals either alone or in combination with NPY Y2 receptor agonists including peptide (PYY) (3-36), analogs thereof and to peptide fragments of PYY(3-36), e.g. PYY(22-36) and PYY(25-36), and analogs thereof such as to control food intake in mammals, blood pressure, cardiovascular response, libido, circadian rhythm, hyperlipidimia, chronic pancreatitis, and nonalcoholic fatty liver disease including nonalcoholic steatohepatitis.
Owner:UNIVERSITY OF CINCINNATI
Therapeutic peptides
The present invention relates to novel analogs of PYY that have an improved therapeutic profile when compared to native human PYY. These novel PYY analogs are useful in the treatment of obesity, diabetes, and other disorders.
Owner:GLAXOSMITHKLINE INTPROP DEV LTD
Modified Dynorphin Expression in Animals and Identification of Compounds for Treatment of Obesity and Diabetes
InactiveUS20090233840A1Reduce additionalReducing glucose intolerancePeptide/protein ingredientsMetabolism disorderFeeding disorderFat mass
The present invention provides novel transgenic animal models of reduced dynorphin expression in humans that are useful for identifying compounds that are antagonists, inverse agonists, agonists or mimetics of one or more dynorphin peptide products of preprodynorphin. The compounds identified in such screening assays are useful in contexts related to the treatment of obesity and type II diabetes including, for example, improving weight loss and / or reducing appetite during dieting; treating feeding disorders; and for modifying fat mass and reducing glucose intolerance in males.
Owner:GARVAN INST OF MEDICAL RES
Regulation of specific spinal neurons regulating pain transmission via chimeric toxins
ActiveUS9447405B2Long-lasting and/or stable and/or reversiblePeptide/protein ingredientsPharmaceutical delivery mechanismPeptide ligandToxin
A chimeric toxin is disclosed comprising a peptide ligand specifically targeting neurons involved in pain processing; and a clostridial neurotoxin light chain, wherein the ligand is linked to the light chain. The methods of preparing such chimeric toxin and the method of using the chimeric toxin to regulate pain transmission are also disclosed.
Owner:RGT UNIV OF CALIFORNIA +1
Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
Provided herein are neuropeptide-2 receptor agonists of the formula (I): Y—R1—R2—X—R3—R4—R5—R6—R7—R8—R9—R10—R11—R12—R13—R14—NH2 (I), as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.
Owner:F HOFFMANN LA ROCHE & CO AG
Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
Provided herein are neuropeptide-2 receptor agonists of the formula (I):as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. X is 4-oxo-6-(1-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa). These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.
Owner:F HOFFMANN LA ROCHE INC
Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
Owner:JANSSEN PHARMA NV
Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors
The present invention comprises compounds of Formula I.wherein:Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.
Owner:JANSSEN PHARMA NV
Methods and compositions related to improving properties of pharmacological agents targeting nervous system
InactiveUS8435940B2Improve blood-brain barrier permeabilityIncreased lipophilic characterBiocideNervous disorderNervous systemMedicine
Disclosed are compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system.
Owner:UNIV OF UTAH RES FOUND
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com